+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID06462092

Phase III Study of Sacituzumab Govitecan with Intrathecal Chemotherapy for Treating Leptomeningeal Metastases from HER2-negative Breast Cancer

Led by Guangzhou Medical University · Updated on 2025-09-29

34

Participants Needed

1

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Leptomeningeal metastases LM is a serious and often fatal complication in patients with HER2-negative breast cancer, involving cancer cells spreading within the space around the brain and spinal cord. This clinical trial aims to evaluate the safety, feasibility, and potential benefits of combining Sacituzumab Govitecan with intrathecal pemetrexed chemotherapy as a new treatment approach for LM from HER2-negative breast cancer. The study is an open-label, uncontrolled Phase III trial designed to address the challenges of treating this condition, which currently has a median survival of only 3 to 6 months despite existing treatments. Participants receive Sacituzumab Govitecan intravenously at a dose of 10 mgkg on Days 1 and 8 of each 21-day treatment cycle until the disease worsens or side effects become unacceptable. Intrathecal pemetrexed chemotherapy is given via intracerebroventricular or lumbar puncture starting on Day 2, delivered in three phases induction therapy 15 mg twice weekly for 2 weeks, consolidation therapy once weekly for 4 weeks, and maintenance therapy once monthly for patients who respond well, continuing until relapse or death. Phase I involved 3 to 6 patients to assess dose tolerance, with possible dose adjustments based on side effects before moving to Phase II. During the study, participants undergo regular monitoring for side effects and treatment response, including assessment of the maximal tolerated dose and clinical response rate over the treatment period and up to two months after. Safety is closely observed through treatment-related adverse event tracking. The studys total duration includes initial treatment cycles and follow-up to evaluate ongoing effects and tolerability. This comprehensive approach helps researchers understand the treatments potential and safety profiles in this patient group.

CONDITIONS

Brief Title

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Research Team

Z

Zhenyu Pan

G

Guozi Yang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here